259 related articles for article (PubMed ID: 26748387)
1. Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations.
Hicar MD; Chen X; Kalams SA; Sojar H; Landucci G; Forthal DN; Spearman P; Crowe JE
Mol Immunol; 2016 Feb; 70():94-103. PubMed ID: 26748387
[TBL] [Abstract][Full Text] [Related]
2. Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein.
Hicar MD; Chen X; Sulli C; Barnes T; Goodman J; Sojar H; Briney B; Willis J; Chukwuma VU; Kalams SA; Doranz BJ; Spearman P; Crowe JE
PLoS One; 2016; 11(7):e0158861. PubMed ID: 27411063
[TBL] [Abstract][Full Text] [Related]
3. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
McGuire AT; Glenn JA; Lippy A; Stamatatos L
J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
[TBL] [Abstract][Full Text] [Related]
4. Polyfunctional Tier 2-Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor.
Spencer DA; Malherbe DC; Vázquez Bernat N; Ádori M; Goldberg B; Dambrauskas N; Henderson H; Pandey S; Cheever T; Barnette P; Sutton WF; Ackerman ME; Kobie JJ; Sather DN; Karlsson Hedestam GB; Haigwood NL; Hessell AJ
J Immunol; 2021 Mar; 206(5):999-1012. PubMed ID: 33472907
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization.
Navis M; Tran K; Bale S; Phad GE; Guenaga J; Wilson R; Soldemo M; McKee K; Sundling C; Mascola J; Li Y; Wyatt RT; Karlsson Hedestam GB
PLoS Pathog; 2014 Aug; 10(8):e1004337. PubMed ID: 25166308
[TBL] [Abstract][Full Text] [Related]
6. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
7. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
[TBL] [Abstract][Full Text] [Related]
8. A single mutation turns a non-binding germline-like predecessor of broadly neutralizing antibody into a binding antibody to HIV-1 envelope glycoproteins.
Yuan T; Li J; Zhang MY
MAbs; 2011; 3(4):402-7. PubMed ID: 21540646
[TBL] [Abstract][Full Text] [Related]
9. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.
Shen G; Upadhyay C; Zhang J; Pan R; Zolla-Pazner S; Kong XP; Hioe CE
PLoS One; 2015; 10(10):e0141233. PubMed ID: 26491873
[TBL] [Abstract][Full Text] [Related]
10. Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes.
Das S; Boliar S; Mitra N; Samal S; Bansal M; Koff WC; Chakrabarti BK
Retrovirology; 2016 Nov; 13(1):81. PubMed ID: 27871328
[TBL] [Abstract][Full Text] [Related]
11. Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies.
Zhu Z; Qin HR; Chen W; Zhao Q; Shen X; Schutte R; Wang Y; Ofek G; Streaker E; Prabakaran P; Fouda GG; Liao HX; Owens J; Louder M; Yang Y; Klaric KA; Moody MA; Mascola JR; Scott JK; Kwong PD; Montefiori D; Haynes BF; Tomaras GD; Dimitrov DS
J Virol; 2011 Nov; 85(21):11401-8. PubMed ID: 21880764
[TBL] [Abstract][Full Text] [Related]
12. Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.
Chukwuma VU; Kose N; Sather DN; Sapparapu G; Falk R; King H; Singh V; Lampley R; Malherbe DC; Ditto NT; Sullivan JT; Barnes T; Doranz BJ; Labranche CC; Montefiori DC; Kalams SA; Haigwood NL; Crowe JE
PLoS One; 2018; 13(12):e0209437. PubMed ID: 30566528
[TBL] [Abstract][Full Text] [Related]
13. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
[TBL] [Abstract][Full Text] [Related]
14. Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development.
Andrabi R; Su CY; Liang CH; Shivatare SS; Briney B; Voss JE; Nawazi SK; Wu CY; Wong CH; Burton DR
Immunity; 2017 Sep; 47(3):524-537.e3. PubMed ID: 28916265
[TBL] [Abstract][Full Text] [Related]
15. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site.
Sundling C; Li Y; Huynh N; Poulsen C; Wilson R; O'Dell S; Feng Y; Mascola JR; Wyatt RT; Karlsson Hedestam GB
Sci Transl Med; 2012 Jul; 4(142):142ra96. PubMed ID: 22786681
[TBL] [Abstract][Full Text] [Related]
16. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
[TBL] [Abstract][Full Text] [Related]
17. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
18. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.
Li L; Wang XH; Williams C; Volsky B; Steczko O; Seaman MS; Luthra K; Nyambi P; Nadas A; Giudicelli V; Lefranc MP; Zolla-Pazner S; Gorny MK
Mol Immunol; 2015 Aug; 66(2):364-74. PubMed ID: 25965315
[TBL] [Abstract][Full Text] [Related]
19. Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.
Gift SK; Leaman DP; Zhang L; Kim AS; Zwick MB
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978711
[TBL] [Abstract][Full Text] [Related]
20. On the benefits of sin: can greater understanding of the 1F7-idiotypic repertoire freeze enhance HIV vaccine development?
Parsons MS; Muller S; Kohler H; Grant MD; Bernard NF
Hum Vaccin Immunother; 2013 Jul; 9(7):1532-8. PubMed ID: 23571168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]